United Therapeutics (UTHR) Cash from Investing Activities Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | -91.04% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 33.61% |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | -2.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.61% |
| Mar 31, 2026 | 75.05% |
| Dec 31, 2025 | -6.33% |
| Sep 30, 2025 | 51.81% |
| Jun 30, 2025 | -21.07% |
| Mar 31, 2025 | 22.89% |
| Dec 31, 2024 | 14.31% |
| Sep 30, 2024 | 21.32% |
| Jun 30, 2024 | -17.83% |
| Mar 31, 2024 | 391.47% |
| Dec 31, 2023 | 38.55% |
| Sep 30, 2023 | -4.87% |
| Jun 30, 2023 | 15.41% |
| Mar 31, 2023 | -100.09% |
| Dec 31, 2022 | -69.38% |
| Sep 30, 2022 | 31.98% |
| Jun 30, 2022 | -58.30% |
| Mar 31, 2022 | -81.28% |
| Dec 31, 2021 | -39.45% |
| Sep 30, 2021 | 10.58% |